Phase 2 study of CHOP-R-14 followed by (90)Y-ibritumomab tiuxetan in patients with previously untreated diffuse large B-cell lymphoma

The aim of this open-label, single-center, phase 2 study was to assess the efficacy and safety of dose-dense CHOP-R-14 followed by (90)Y-ibritumomab radioimmunotherapy (RIT) in patients with previously untreated diffuse large B-cell lymphoma (DLBCL). A total of 20 patients, the majority presenting w...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Mol Clin Oncol
Main Authors: Karmali, Reem, Larson, Melissa L., Shammo, Jamile M., Gregory, Stephanie A., O'Brien, Teresa, Venugopal, Parameswaran
Formato: Artigo
Idioma:Inglês
Publicado em: D.A. Spandidos 2017
Assuntos:
Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5374906/
https://ncbi.nlm.nih.gov/pubmed/28413681
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mco.2017.1169
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados